^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
29P - Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer
Published date:
05/03/2021
Excerpt:
...we assessed whether the combination of bevacizumab/paclitaxel yields sufficient anti-tumor activity to justify further exploration in advanced ER+/HER2- breast cancer patients with acquired ESR1 mutations in circulating tumor DNA (ctDNA)....The 6-month PFS rate was 83% for ESR1 wild-type patients versus 85% for ESR1 mutant patients (17/20)....This explorative study indicates that in advanced breast cancer patients with ESR1 mutations in plasma it is worthwhile to start bevacizumab/paclitaxel as further treatment.
Secondary therapy:
bisphosphonate bound paclitaxel
